SPECIAL FEATURES

Dual PI3K/mTOR Inhibitors: Does p53 Modulate Response? 3719
Oleksandr Eksheyan, Arunkumar Anandharaj, and Cherie-Ann O. Nathan
See article, p. 3808

Use of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug Approvals 3722
Michael B. Shea, Samantha A. Roberts, Jessica C. Walrath, Jeff D. Allen, and Ellen V. Sigal

Molecular Pathways

Environmental Estrogens Activate Nongenomic Signaling to Developmentally Reprogram the Epigenome 3732
Rebecca Lee Yean Wong and Cheryl Lyn Walker

Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers 3738
Valerie Gordon and Shantanu Banerji

Optical Image-Guided Cancer Surgery: Challenges and Limitations 3745
Stijn Keereweer, Pieter B.A.A. Van Driel, Thomas J.A. Snoeks, Jeroen E. Reutenburg de Jong, Robert J. Baatenburg de Jong, Alexander L. Vahrmeijer, Henricus J.C.M. Sterenborg, and Clemens W.G.M. Löwik

Review

TGFβ Cytokines from Malignant Cells Suppress Tα1 Responses and Enforce a Global TGFβ Bias in Leukemic Cutaneous T-cell Lymphoma 3755
Emmanuella Guenova, Rei Watanabe, Jessica E. Teague, Jennifer A. Desimone, Ying Jiang, Mitra Dowlatshahi, Christoph Schlapbach, Knut Schuekel, Alain H. Rook, Marianne Tawa, David C. Fisher, Thomas S. Kupper, and Rachael A. Clark

S100B Promotes Glioma Growth through Chemotraction of Myeloid-Derived Macrophages 3764
Huaqing Wang, Leying Zhang, Ion Y. Zhang, Xuebo Chen, Anna Da Fonseca, Shihua Wu, Hui Ren, Sam Badie, Sam Sadeghi, Mao Ouyang, Charles D. Warden, and Behnam Badie

Glioma Grade Is Associated with the Accumulation and Activity of Cells Bearing M2 Monocyte Markers 3776

Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma 3787

CANCER THERAPY: PRECLINICAL

Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy 3796
Yi-Xiang Zhang, Jolieke G. van Oosterwijk, Ewa Sicinska, Samuel Moss, Stephen P. Remillard, Tom van Wezel, Claudia Buhmann, Andrew B. Hassan, George D. Demetri, Judith V.M.G. Bovée, and Andrew J. Wagner
PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Marine Knockout Models of Head and Neck Cancer
See commentary, p. 3719

Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
Emanuela Grassilli, Robert Narloch, Elena Federzoni, Leonarda Ianzano, Fabio Pisano, Roberto Giovannoni, Gabriele Romano, Laura Masiero, Biagio Eugenio Leone, Serena Bonin, Marisa Donada, Giorgio Stanta, Kristian Helin, and Marialuisa Lavitrano

Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia
David P. Conrad, Jovian Tsang, Meaghan Maclean, Jean-Simon Diallo, Fabrice Le Boeuf, Chantal G. Lemay, Teresa J. Falls, Kelley A. Parato, John C. Bell, and Harold L. Atkins

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik, Bree Foley, Bin Zhang, Michael R. Verneris, Erica Warlick, Michelle K. Gleason, Julie A. Ross, Xianghua Luo, Daniel J. Weisdorf, Bruce Walcheck, Daniel A. Vallera, and Jeffrey S. Miller

Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2

Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts
Rebecca Voltan, Paola Secchiero, Barbara Ruosi, Flavio Forni, Chiara Agostinis, Lorenzo Caruso, Maria Angela Vandelli, and Giorgio Zauli

Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
Lana McClements, Anita Yakkundi, Angelos Papapipropoulos, Hannah Harrison, Matthew P. Ablett, Puthen V. Jithesh, Hayley D. McKeen, Rachel Bennett, Christopher Donley, Adrien Kissenpfennig, Stuart McIntosh, Helen O. McCarthy, Eric O’Neill, Robert B. Clarke, and Tracy Robson

USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer

Ketogenic Diets Enhance Oxidative Stress and Radio-Chemo-Therapy Responses in Lung Cancer Xenografts
Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma

Wen-Wei Zhu, Jia-Jian Guo, Lei Guo, Hu-Liang Jia, Ming Zhu, Ju-Bo Zhang, Christopher A. Loffredo, Marshonna Forgues, Hua Huang, Xu-Jian Xing, Ning Ren, Qiong-Zhu Dong, Hai-Jun Zhou, Zheng-Gang Ren, Nai-Qing Zhao, Xin Wei Wang, Zhao-You Tang, Lun-Xiu Qin, and Qing-Hai Ye

The Prognostic Value of MicroRNAs Varies with Patient Race/Ethnicity and Stage of Colorectal Cancer

Liselle C. Bovell, Chandrakumar Shanmugam, Balananda-Dhurjati K. Putcha, Venkat R. Katoori, Bin Zhang, Sejong Bae, Karen P. Singh, William E. Grizzle, and Upender Manne

Antibiotic Treatment Decreases Microbial Burden Associated with Pseudomyxoma Peritonei and Affects β-Catenin Distribution

Cristina Semino-Mora, Traci L. Testerman, Hui Liu, Jeannette M. Whitmire, Kimberly Studeman, Yali Jia, Thomas J. McAvoy, Jennifer Francis, Carol Nieroda, Armando Sardi, D. Scott Merrell, and Andre Dubois

Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

Yan Feng, Amit Roy, Eric Masson, Tai-Tsang Chen, Rachel Humphrey, and Jeffrey S. Weber

Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

Kimmie Ng, Josep Tabernero, Jimmy Hwang, Emilio Bajetta, Sunil Sharma, Salvatore A. Del Prete, Edward R. Arrowsmith, David P. Byam, Michaela Sedova, Jin Jin, Kamel Malek, and Charles S. Fuchs

Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors

Andrew J. Brenner, Yael C. Cohen, Eyal Breitbart, Livnat Bangio, John Sarantopoulos, Francis J. Giles, Ernest C. Borden, Dori Harats, and Pierre L. Triozzi

Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer

Vered Stearns, Lisa K. Jacobs, Marylo Fackler, Theodore N. Tsangaris, Michelle A. Rudek, Michaela Higgins, Julie Lange, Zandra Cheng, Shannon A. Slater, Stacie C. Jeter, Penny Powers, Susanne Briest, Calvin Chao, Carl Yoshizawa, Elizabeth Sugar, Igor Espinoza-Delgado, Saraswati Sukumar, Edward Gabrielson, and Nancy E. Davidson

PD-L1 Expression in B-cell Lymphomas and Virus-Associated Malignancies—Letter

Mads Hald Andersen

Correction: Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAF<sup>V600E</sup> Colorectal Cancer

For more information please visit www.aacrjournals.org
ABOUT THE COVER

β-catenin is a transmembrane protein that associates with junctional proteins and assists with the maintenance of cell attachment. As revealed through immunofluorescent staining, β-catenin (shown in green) localizes to the cell membranes and within the lateral junctional complex in normal appendix tissue. In contrast, tissue samples from patients with pseudomyxoma peritonei display primarily cytoplasmic staining of β-catenin and virtually no staining at the intercellular boundaries. However, antibiotic treatment of patients with pseudomyxoma peritonei results in a significant increase in β-catenin within the cell membranes, appearing to aid in the renormalization of β-catenin distribution. For details, see the article by Semino-Mora and colleagues on page 3966 of this issue.